Association between sodium-glucose co-transporter 2 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a nationwide population-based cohort study.
Sheng-Hsiang MaC Y WuY S LyuY J ChouY T ChangChen-Yi WuPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
The risk of BP did not increase in patients receiving SGLT2i. Thus, SGLT2i could be a safe choice for patients with diabetes having additional risk factors or a history of BP.
Keyphrases